USS Investment Management Ltd Sells 1,440 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

USS Investment Management Ltd lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,202 shares of the biopharmaceutical company’s stock after selling 1,440 shares during the period. USS Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $12,969,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. OLD Second National Bank of Aurora raised its holdings in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 15 shares during the last quarter. Rakuten Securities Inc. grew its holdings in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares during the last quarter. TD Private Client Wealth LLC increased its position in Regeneron Pharmaceuticals by 9.6% in the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 15 shares during the period. Manchester Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 12.6% during the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 18 shares during the last quarter. Finally, Financial Perspectives Inc lifted its holdings in shares of Regeneron Pharmaceuticals by 10.9% during the fourth quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 19 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on REGN. Cantor Fitzgerald began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 target price for the company. UBS Group lowered their price objective on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. TD Cowen decreased their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. Finally, The Goldman Sachs Group lowered their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $890.60.

Regeneron Pharmaceuticals Stock Up 3.1%

Shares of NASDAQ:REGN opened at $614.79 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 52-week low of $520.50 and a 52-week high of $1,211.20. The business’s 50 day simple moving average is $596.79 and its two-hundred day simple moving average is $679.72. The firm has a market cap of $66.38 billion, a P/E ratio of 16.06, a PEG ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the prior year, the business earned $9.55 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was down 3.7% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.57%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.